DexCom vs Tandem

DexCom and Tandem are two prominent companies in the rapidly growing field of diabetes management technology. DexCom is known for its continuous glucose monitoring systems, while Tandem is a leader in insulin pump technology. Both companies have seen significant growth and innovation in recent years, making them key players in the diabetes market. Investors and analysts closely follow the stock performance of DexCom and Tandem, as they continue to revolutionize the way individuals with diabetes manage their condition.

DexCom or Tandem?

When comparing DexCom and Tandem, different investors may prioritize various metrics based on their investment strategies and goals. So, ask yourself what type of investor you are. This will guide you in determining which metrics are most important for your investment decision between DexCom and Tandem.

Dividend Investors:

Dividend investors look for stable and growing income streams, using dividend metrics to assess potential investments. A company's dividend yield essentially measures the size of its dividend relative to the total market value of the company. DexCom has a dividend yield of -%, while Tandem has a dividend yield of -%. Beyond the yield itself, considering the growth and sustainability of these dividends is also crucial. DexCom reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%. On the other hand, Tandem reports a 5-year dividend growth of 9.52% year and a payout ratio of -40.74%.

Value Investors:

Value investors focus on financial metrics to determine a stock's intrinsic value compared to its market value. The Price-to-Earnings (P/E) Ratio links stock price to a company's earnings per share, with DexCom P/E ratio at 40.17 and Tandem's P/E ratio at -10.04. Another crucial valuation metric is the Price-to-Book (P/B) Ratio, which compares stock price with book value per share. DexCom P/B ratio is 11.00 while Tandem's P/B ratio is 0.38.

Growth Investors:

Growth investors prioritize metrics indicative of a company's expansion potential. Focusing on top-line growth, DexCom has seen a 5-year revenue growth of 2.21%, while Tandem's is -0.37%. Return on Equity (ROE) measures how effectively a company uses equity investment to generate earnings, with DexCom's ROE at 29.58% and Tandem's ROE at -3.76%.

Retail Investors:

Retail investors often consider stock affordability and company familiarity. For example, day low prices are $67.05 for DexCom and £156.20 for Tandem. Over the past year, DexCom's prices ranged from $62.34 to $142.00, with a yearly change of 127.78%. Tandem's prices fluctuated between £69.75 and £249.30, with a yearly change of 257.42%. Brand recognition also plays a role, as familiarity with a company can influence investment decisions.